Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of the integra® titan™ modular shoulder system generation 2.5 for primary shoulder joint replacement

Conditions: Osteo Arthritis Shoulders; Traumatic Arthritis; Rheumatoid Arthritis

Summary: a post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the titan modular shoulder system 2.5 when used for primary shoulder arthroplasty.


Eligibility criteria:
inclusion criteria: * for total shoulder arthroplasty, subjects must meet a, b, or c below: 1. severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis 2. fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory 3. other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component) * for shoulder hemiarthroplasty, subjects must meet any of the sub-criteria a - g below: 1. severely painful and/or disabled joint resulting from osteoarthritis, traumatic arthritis or rheumatoid arthritis 2. fracture-dislocations of the proximal humerus where the articular surface is severely comminuted, separated from its blood supply or where the surgeon's experience indicates that alternative methods of treatment are unsatisfactory 3. other difficult clinical problems where shoulder arthrodesis or resection arthroplasty are not acceptable (e.g. -revision of a failed primary component) 4. ununited humeral head fractures 5. avascular necrosis of the humeral head 6. rotator cuff arthropathy 7. deformity and/or limited motion exclusion criteria: * absent, irreparable or nonfunctional rotator cuff or other essential muscles. * have an active local or systemic infection. * have inadequate bone stock in the proximal humerus or glenoid fossa for supporting the components. * have poor bone quality such as osteoporosis where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid. * have a muscular, neurologic, or vascular deficiencies that compromise the affected extremity. * have a known sensitivity or allergic reaction to one or more of the implanted materials. * have a condition that may impair proper wound healing.
non-invasive evaluation of portal pressure by mri

Conditions: Chronic Liver Disease

Summary: the objective of this research is to study the correlation between the portosystemic pressure gradient and azygos blood flow measured by mri.

all patients will benefit from: * pressure gradient measurement portosystemic * mri measurement of azygos flow, aortic, portals, spleen and lower cellar * liver biopsy * laboratory tests

Eligibility criteria:
inclusion criteria: * suspicion of chronic liver disease * indication to perform a liver biopsy transjugular * patient able to consent exclusion criteria: * contraindication to mri: * holders of a pacemaker or a defibrillator, an implanted material activated by electrical, magnetic or mechanical * holders of hemostatic clips intracerebral aneurysms or carotid arteries, bearing orthopedic implants * claustrophobic * severe hepatic encephalopathy * inability to mri in the week surrounding the first jugular

Keywords: portal pressure portosystemic pressure gradient azygos blood flow
kinesio taping and inhibitory treatment techniques

Conditions: Fibromyalgia

Summary: objective: compare the benefits of kinesio taping and inhibitory treatment techniques for cervical, thoracic and lumbar spine in patients with fibromyalgia syndrome (fms). study design: a single-blind randomized controlled trial was conducted on patients with fms. setting: clinical setting. methods: sixty-four subjects with fms were randomly assigned to an experimental group receiving kinesio taping and inhibitory treatment techniques, or to a control group for exercises and electrical stimulation therapy.


Eligibility criteria:
inclusion criteria: * diagnosed fibromyalgia syndrome. * limitation of usual activities due to pain on at least 1 day in the previous 30 days. * agreement to attend evening therapy sessions. * non-practice of regular physical activity. exclusion criteria: * a history of surgery. * the presence of comorbid conditions (e.g., morbid obesity, inflammatory diseases, irritable bowel syndrome and interstitial cystitis). * a history of whiplash injury. * severe physical disability. * uncontrolled endocrine disorders (e.g., hyperthyroidism, diabetes); 6) illness (e.g., schizophrenia or substance abuse). * the use of medication other than as-needed analgesics (excluding long-term narcotics). * malignancy. * psychiatric disorders. * a score of ≥ 9 points in the beck depression inventory.

Keywords: physical therapy modalities exercise electrical stimulation therapy bandages
study of histological findings of the internal inguinal ring in patients with indirect inguinal hernia

Conditions: Indirect Inguinal Hernia

Summary: the histology of the internal inguinal ring in patients with indirect hernia submitted to elective surgery was studied. in contrast with recently published studies, the investigators believe that histological findings of the internal inguinal ring would reflect those associated and expected with normal aging.


Eligibility criteria:
inclusion criteria: * male gender * older than 15 years-of-age * unilateral indirect inguinal hernia * non-smokers * non-diabetics * non-connective tissue conditions * primary inguinal hernia exclusion criteria: * female gender * younger than 15 years-of-age * bilateral inguinal hernia * direct or combined direct-indirect inguinal hernia * femoral hernia * smokers * diabetics * other connective tissue diseases * recurrent inguinal hernia

Keywords: inguinal hernia inguinal ring histology hernioplasty lichtenstein
clinical comparison between stainless-steel crown, zirconia crown and bioflx crown in primary molars

Conditions: Decayed Teeth; Carious Lesion

Summary: the purpose of this clinical trial was to compare clinically three different crowns for primary molars; stainless steel crown, zirconia crown and bioflx crown. the main questions it aims to answer are: is bioflex crown is an alternative to stainless steel crown and zirconia crown? seventy-five patients their age range between 3 and 8 years participated in this study. the participants are divided into three groups representing group a for stainless steel crown (n=25), group b for zirconia crown (n=25) and group c for bioflx crown (n=25). plaque index, crown retentivity and gingival index will be evaluated at evaluated at baseline, 6 and 12 months.


Eligibility criteria:
inclusion criteria: * patient within the age group of 3-8 years old. * healthy children free of any systemic disease. * pulpotomized or pulpectomized (endodontically treated) lower second primary molars. * patients who have the behavioral rating of definitely positive or positive according to the frankl behaviour. exclusion criteria: * • patient younger than 3 years old or older than 8 years old. * non-healthy children or have any systemic disease. * primary molars with no pulpal treatment * patients who have the behavioral rating of definitely negative or negative according to the frankl behaviour.

Keywords: primary molars stainless steel crown zirconia crown bioflx crown clinical evaluation
added value of inreach software on performance characteristics of standard bronchoscopy

Conditions: Lung Disease

Summary: the study is aimed to evaluate and describe the added value of inreach planning software on performance characteristics of standard bronchoscopy.


Eligibility criteria:
inclusion criteria: * candidates for non-emergency bronchoscopy * must provide signed informed consent * male or female above 18 years old * lung lesions up to 3 cm in size (in largest diameter), non-visible by standard bronchoscope exclusion criteria: * ct done over a month before the bronchoscopy procedure

Keywords: known or suspected lung disease candidates for non-emergency bronchoscopy
tablet vs. liquid suspension ibuprofen in the relief of pain

Conditions: Pharyngitis

Summary: ibuprofen (also known as advil or motrin) is a medication that is known to reduce pain. it is also known that ibuprofen levels in the blood rise higher and faster if the medication is taken in liquid suspension. this study will attempt to determine if ibuprofen suspended in a liquid works to relieve sore throat pain faster than pills of ibuprofen. it will also determine whether patients with sore throat prefer to take pill or liquid form of the medication.

pain is a common emergency and urgent care complaint. ibuprofen is known to be an effective treatment for many forms of pain. sore throat has been established to be an acceptable model of analgesic effect, and ibuprofen has been found to offer relief in studies of sore throat. several studies have demonstrated that ibuprofen in suspension is absorbed into the system more quickly and results in earlier maximum blood concentrations. to date, no study has evaluated onset to analgesia as reported by the patient for suspension versus tablet formation of ibuprofen in an emergency department population presenting with complaints of sore throat. this is a double blinded randomized placebo controlled trial to compare suspension versus tablet ibuprofen in an emergency department population presenting with sore throat. the purpose of this study is to assess whether ibuprofen in suspension form results in relief of pain more quickly than the tablet form of an equivalent dose of ibuprofen. we will also determine if there is an interval difference from time of analgesia administration to perception of analgesia that is clinically significant.

Eligibility criteria:
inclusion criteria: * age greater than 12 years and less than 65 years * weight \> 40 kg * a provider order for ibuprofen to address pharyngitis pain. * initial numeric pain score \> 6 exclusion criteria: * known allergy or hypersensitivity to aspirin or nsaids * inability to swallow pills * inability to carry out informed consent in english * inability to complete a visual analog pain scale * a concomitant order for another class of analgesic * use of analgesic within 8 hours * known 3rd trimester pregnancy * significant medical conditions where participation would pose an unnecessary barrier to ongoing care. * those taking opioid medications for more than 3 days * weight \< 40 kg
gastric volume and colorectal surgery

Conditions: Postoperative Ileus

Summary: postoperative ileus (poi) is a serious complication after colorectal surgery. one of its most frequent consequences is the replacement of nasogastric tube because of the vomiting. vomiting is due to the distension of the stomach and information on the evolution of gastric filling after surgery could help to better understand the physiopathology of poi. it could also give indication to help the physician in the management of poi. the ultrasonography has been shown to be a reliable technic to assess the gastric emptying. to date, there is no indication in the literature about the evolution of the gastric filling after colorectal surgery while these information could help to identify patients at risk for poi and to predict the need for poi replacement.


Eligibility criteria:
inclusion criteria: * patient undergoing colorectal resection whatever the surgical access exclusion criteria: * contra-indication to ultrasonography performance * history of gastrectomy
the impact of a helplessness and recovery of an empowerment intervention on people diagnosed with schizophrenia: findings from a randomized controlled trial

Conditions: Psychotic Disorders

Summary: a randomized controlled trial was conducted from november 2015 and may 2016 with 112 participants of people diagnosed with schizophrenia. participants aged 18 years or older with diagnostic statistical manual (dsm-v) schizophrenia or schizoaffective disorder from outpatient mental health clinics in jordan, were randomly assigned participants either to receive 6 weeks of a booklet form of intervention with face to face discussion, and treatment as usual (tau) (intervention, n = 56), or tau (control, n = 56). participants were assessed at baseline, immediately post-intervention (post-treatment1) and at three months follow-up. the primary outcome measure was change in helplessness score . secondary outcomes for pdws were psychiatric symptoms, recovery rate and quality of life.

a randomized controlled trial was conducted from november 2015 and may 2016 with 112 participants of people diagnosed with schizophrenia. participants aged 18 years or older with dsm-v schizophrenia or schizoaffective disorder from outpatient mental health clinics in jordan, were randomly assigned participants either to receive 6 weeks of a booklet form of intervention with face to face discussion, and treatment as usual \[tau\] (intervention, n = 56), or tau (control, n = 56). participants were assessed at baseline, immediately post-intervention (post-treatment1) and at three months follow-up. the primary outcome measure was change in helplessness score . secondary outcomes for pdws were psychiatric symptoms, recovery rate and quality of life.

Eligibility criteria:
inclusion criteria: * adult aged 16 years or more * able to read and write in an arabic * able to consent * diagnosed with schizophrenia * volunteers exclusion criteria: * learning disability * not able to read or write
the use of a ultra-sound of the lung to diagnose lung diseases

Conditions: Pulmonary Pathologies; Cardio-pulmonary Diseases

Summary: the study is a prospective open evaluating study of ultrasound/doppler application to the chest cavity intended to detect and characterize pathologies of the pulmonary and cardio-vascular system. the system is a noninvasive non-imaging device designated to monitor flow and movement velocity and display the data continuously.


Eligibility criteria:
inclusion criteria: * age 18y or older * patients who are clinically suspected of having a significant pulmonary or cardio-pulmonary disease * patients with chf * patients with pulmonary hypertension * patients with copd * patients with asthma * signed informed consent * normal subjects exclusion criteria: * patients with unstable conditions: unstable angina, uncontrolled chf, etc * inability to assume a sitting or supine position * patients with severe chest wall deformity
subject reported outcomes with use of adapalene 0.3% - benzoyl peroxide (bpo) 2.5% in dark skin acne

Conditions: Acne Vulgaris

Summary: this is a multicenter open-label, prospective study in subjects with dark skin from one of the 3 ethnic/race backgrounds: asian, latin american and black/african-american and with moderate to severe acne vulgaris on the face. all eligible subjects will receive adapalene 0.3% - bpo 2.5% gel (epiduo forte/tactupump forte) once daily on whole face. the purpose of this trial is to evaluate subject reported outcomes with the combination of adapalene 0.3% - bpo 2.5%, epiduo forte / tactupump forte gel, after 16 weeks of treatment of moderate to severe acne in dark skin phototypes (iv to vi).


Eligibility criteria:
inclusion criteria: * subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by: 1. investigator's global assessment (iga) score of 3 (moderate) or 4 (severe ); and 2. a minimum of 25-100 inflammatory lesions (papules and pustules); and 3. a minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total (excluding the nose); and 4. no more than two acne nodules (≥ 1 cm), * subject with skin phototype iv to vi on fitzpatrick skin phototype scale, * subjects from one of the 3 ethnic/race backgrounds: asian, latin american and black/african-american, exclusion criteria: * subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, acne requiring systemic treatment, * subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea * female subject who is pregnant, lactating or planning a pregnancy during the trial, * subjects having received at least one of the following topical treatments on the treated area: corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxyacids, zinc containing treatments, antiseptics, other anti-inflammatory products or other acne treatments (2 weeks); retinoids (4 weeks); cosmetic/aesthetic procedures on the face (1 week); wax epilation (2 weeks); photodynamic therapy (6 weeks); laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne (3 months). * subjects having received at least one of the following systemic treatments: corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); oral retinoids/isotretinoin/ anti-androgens / cyproterone acetate / chlormadinone acetate (6 months); spironolactone/ drospirenone (3 months); immunomodulators (3 months) and oral contraceptives/ oral dapsone for acne(1 month).

Keywords: acne dark skin
three modalities of treatment in operable and resectable stage iiia (t1-3, n2) non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer

Summary: stage iiia non-small cell lung cancers comprising a mediastinal ganglionic invasion n2 account for 20 to 30% of the nsclcs. they are almost always potentially resectable, but the results obtained by surgery alone or surgery followed by chemotherapy (ct) and/or radiotherapy (rt) are insufficient. the neoadjuvant approach was tested, in randomized tests of exclusive ct, or in noncomparative tests of rt-ct.

these results justify the choice of the study design currently suggested, testing the preoperative feasibility 1. chemotherapy: cisplatin-gemzar (arm a) or 2. chemoradiotherapy: cisplatin-navelbine-radiotherapy (arm b) or carboplatin-taxol-radiotherapy (arm c). the results obtained, in terms of feasibility and toxicity, will make it possible to select the optimal diagrams for a phase iii study.

Eligibility criteria:
inclusion criteria: * operable and resectable stage iiia (t1-3, n2) nsclc * world health organization (who) performance status of 1 or less exclusion criteria: * severe cardiac, respiratory, renal or hepatic failure

Keywords: operable and resectable stage iiia (t1-3, n2) nsclc
preterm infants and nephrocalcinosis

Conditions: Prematurity; Nephrocalcinosis; Hypercalciuria

Summary: nephrocalcinosis (nc), defined as calcification of renal tissue, has been reported to occur in 7-41% of premature infants. causes of nc are likely multi-factorial, and infants born prematurely and with very low birth weight (\<1500 gm) seem to be at the highest risk of developing nc. recent changes in recommendations for nutrition for the preterm infant such as higher intakes of protein, calcium, and vitamin d may also play a factor in the pathogenesis of nc. currently, diagnosis of nc often occurs incidentally during ultrasound evaluation for other issues. because there is no acute symptom or pattern of symptoms in the preterm population associated specifically with nc, it is possible that many cases of nc may not be diagnosed. presently, it is impractical and costly to screen all infants for nc with renal ultrasound, therefore there is no standard of care regarding screening for nc. nc may have long-term effects. studies have shown that preterm infants with nc had shorter kidneys and a lower rate of tubule resorption of phosphorus (trp) than preterm infants without nc. this study will analyze weekly urinalysis for all enrolled subjects prospectively and then look at the incidence of nc at discharge of the enrolled subjects.


Eligibility criteria:
inclusion criteria: * infants whose gestation less than or equal to 32 weeks and/or birth weights less than 1800 gm exclusion criteria: * infants with congenital abnormalities of the heart, lung, gi, or kidneys that will affect renal function.
mechanistic studies of psilocybin in headache disorders

Conditions: Migraine

Summary: in previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. this purpose of this study is to examine potential sources for this observed effect. this study will measure brain resting state functional connectivity (fmri), central synaptic density (sv2a pet), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep eeg) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent.


Eligibility criteria:
inclusion criteria: * age 21 to 70 (inclusive) * migraine disease per ichd-3 criteria (for migraine participants) or healthy control patient exclusion criterion * unstable medical condition or serious nervous system pathology * pregnant, breastfeeding, lack of adequate birth control * psychotic or manic disorder * substance abuse in the prior 3 months * use of classic psychedelics (e.g., psilocybin, lsd, mescaline) in the past 6 months * use of cannabis or other thc products in the prior 2 weeks * urine toxicology positive to drugs of abuse * the use of triptans (e.g., sumatriptan) or ditans (e.g., lasmiditan) more than twice weekly on average * use of serotonergic preventive therapies (i.e., taken chronically; amitriptyline, fluoxetine, imipramine, cyproheptadine) in the past 6 weeks * use of preventive or transitional treatments that produce spikes and waning of symptom relief (e.g., botulinum toxin, calcitonin gene-related peptide system targeting antibodies, peripheral nerve or ganglion blocks, chiropractic manipulation) * history of a bleeding disorder or are currently taking anticoagulants (e.g., warfarin, enoxaparin, dabigatran, apixaban). * use of non-steroidal anti-inflammatory drugs (nsaids; e.g., ibuprofen, naproxen) in the 7 days before pet scan and 7 days after pet scan.

Keywords: psilocybin resting state functional connectivity synaptic density synaptic vessel glycoprotein 2a (sv2a) circadian rhythm sleep inflammation
mediators of atherosclerosis in south asians living in america

Conditions: Atherosclerosis; Cardiovascular Diseases; Heart Diseases; Coronary Artery Disease; Coronary Disease

Summary: south asian (indian, pakistani, bangladeshi, nepali, and sri lankan) individuals have high rates of cardiovascular disease that is not explained by traditional cardiovascular risk factors. though south asians represent over one-quarter of the world's population, there are no longitudinal studies in this high-risk ethnic group. the investigators aim to establish a longitudinal study of south asians at three united states centers to identify risk factors linked to subclinical atherosclerosis and incident cardiovascular disease. the purpose of this study is to understand the causes of heart disease and stroke in south asians and compare these causes to those in other united states ethnic groups.


Eligibility criteria:
inclusion criteria: * south asian ancestry defined by having at least 3 grandparents born in one of the following countries: india, pakistan, bangladesh, nepal, or sri lanka * age between 40 and 84 years. exclusion criteria: * physician diagnosed heart attack, stroke or transient ischemic attack (tia), heart failure, or angina (or use of nitroglycerin) * current atrial fibrillation * past history of cardiovascular procedures (coronary artery bypass graft (cabg) surgery, angioplasty, valve replacement, pacemaker or defibrillator implantation, or any surgery on the heart or arteries) * active treatment for cancer * life expectancy less than 5 years due to serious medical illness * impaired cognitive ability as judged by the reviewer * plans to move out of the study region in next 5 years * weight greater than 300 pounds * living in a nursing home or on a waiting list * unable to speak/read/write english, hindi, urdu, or bangla